Risk factors for recurrent thrombosis: Prospective study of a cohort of Japanese systemic lupus erythematosus

Angiology

Volumn 56, Issue 5, 2005, Pages 601-609

  Akimoto, Tomohiro ^a,b   Kobayashi, Shigeto ^a,b   Tamura, Naoto ^a,b   Ohsawa, Toshiya ^a,b   Kawano, Terunaga ^a,b   Tanaka, Mitsuhiko ^a,b   Hashimoto, Hiroshi ^a,b  

^a Juntendo University School of Medicine ^*

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BENIDIPINE; CAPTOPRIL; CARDIOLIPIN ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; NIFEDIPINE; NILVADIPINE; PHOSPHOLIPID ANTIBODY; PRAVASTATIN; PROBUCOL; TOCOPHEROL;

ADULT; ARTICLE; ASIAN; CIGARETTE SMOKING; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBESITY; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ADULT; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPERTENSION; JAPAN; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; THROMBOSIS;

EID: 25644443865     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970505600512     Document Type: Article

References (35)

1. Hughes GR: The anticardiolipin syndrome. Clin Exp Rheumatol 3:285-286, 1985.
2. Kittner SJ, Gorelick PB: Antiphospholipid antibodies and stroke: An epidemiological perspective. Stroke 23:I19-I22, 1992.
3. Shah NM, Khamashta MA, Atsumi T, et al: Outcome of patients with anticardiolipin antibodies: A 10-year follow-up of 52 patients. Lupus 7:3-6, 1998.
4. Jouhikainen T, Stephansson E, Leirisalo-Repo M: Lupus anticoagulant as a prognostic marker in systemic lupus erythematosus. Br J Rheumatol 32:568-573, 1993.
5. Tsutsumi A, Matsuura E, Ichikawa K, et al: Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 39:1466-1474, 1996.
6. Thom TJ, Epstein FH, Feldman JJ, et al: Total Mortality and Mortality from Heart Disease, Cancer, and Stroke from 1950 to 1987 in 27 Countries. Bethesda, MD: National Institutes of Health, NIH Pub No 92-3088, 1992.
7. Thom TJ, Epstein FH: Heart disease, cancer, and stroke mortality trends and their interrelations. An international perspective. Circulation 90:574-582, 1994.
8. Takeya Y, Popper JS, Shimizu Y, et al: Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: Incidence of stroke in Japan and Hawaii. Stroke 15: 15-23, 1984.
9. Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277, 1982.
10. Mokuno C, Taniguchi S, Hirose S: [Establishment of determination method for lupus anticoagulant and its clinical significance in systemic lupus erythematosus patients.] 1986 Annual report of the research committee on intractable autoimmune disease, Ministry of Health and Welfare of Japan [in Japanese], 1987, pp 344-351.
11. Ninomiya C, Taniguchi O, Kato T, et al: Distribution and clinical significance of lupus anticoagulant and anticardiolipin antibody in 349 patients with systemic lupus erythematosus. Intern Med 31:194-199, 1992.
12. Loizou S, McCrea JD, Rudge AC, et al: Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): Standardization and quantitation of results. Clin Exp Immunol 62:738-745, 1985.
13. Matsuura E, Igarashi Y, Fujimoto M, et al: Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 148:3885-3891, 1992.
14. Wilson PW, Evance JC: Coronary artery disease prediction. Am J Hypertens 6:309S-313S, 1993.
15. Kannel WB, Wolf PA, Verier J, et al: Epidemiologic assessment of the role of blood pressure in stroke: The Framingham Study. 1970. JAMA 276:1269-1278, 1996.
16. Guidelines sub-committee of the WHO/ISH mild hypertension liaison committee. 1993 guidelines for the management of mild hypertension: Memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 11:905-918, 1993.
17. The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183-1197, 1997.
18. Shirai K: [Evaluation of obesity and diagnostic criteria of obesity as a disease for Japanese] [in Japanese]. Nippon Rinsho 59:578-585, 2001.
19. McNeely MJ, Boyko EJ, Shofer JB, et al: Standard definitions of overweight and central adiposity for determining diabetes risk in Japanese Americans. Am J Clin Nutr 74:101-107, 2001.
20. Durand JM, Lefevre P, Kaplanski G, et al: Accelerated hypertension and nephroangiosclerosis associated with antiphospholipid syndrome. Report of two cases and review of the literature. Clin Rheumatol 13:635-640, 1994.
21. Manzi S, Meilahn EN, Rairie JE, et al: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 145:408-415, 1997.
22. Ward MM: Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42:338-346, 1999.
23. Horkko S, Miller E, Dudl E, et al: Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 98:815-825, 1996.
24. Cervera R, Khamashta MA, Font J, et al: Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 72:113-124, 1993.
25. Cervera R, Font J, Lopez-Soto A, et al: Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: Prospective analysis of a series of 100 patients. Ann Rheum Dis 49:109-113, 1990.
26. Finazzi G, Brancaccio V, Moia M, et al: Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian Registry. Am J Med 100:530-536, 1996.
27. Sebastiani GD, Galeazzi M, Tincani A, et al: Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scand J Rheumatol 28:344-351, 1999.
28. Vaarala O, Alfthan G, Jauhiainen M, et al: Cross-reaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341:923-925, 1993.
29. Lahita RG, Rivkin E, Cavanagh I, et al: Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 36:1566-1574, 1993.
30. Ames PR, Pyke S, Iannaccone L, et al: Antiphospholipid antibodies, haemostatic variables and thrombosis - a survey of 144 patients. Thromb Haemost 73:768-773, 1995.
31. Atsumi T, Khamashta MA, Haworth RS, et al: Arterial disease and thrombosis in the antiphospholipid syndrome: A pathogenic role for endothelin 1. Arthritis Rheum 41:800-807, 1998.
32. Ames PR: Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: A unifying "membrane stress syndrome" hypothesis. Lupus 3:371-377, 1994.
33. Amengual O, Atsumi T, Khamashta MA, et al: Auto-antibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol 36: 964-968, 1997.
34. Del Papa N, Guidali L, Sala A, et al: Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 40:551-561, 1997.
35. Simantov R, LaSala JM, Lo SK, et al: Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 96:2211-2219, 1995.